

AusDiagnostics TODAY



New State-of- the-art Facility



Scientists Justin Snyder (left), Saba Kugashiya (center), and Jalal Kassouah (right) prepare Puryx™ extraction kit components in the new AusDiagnostic state-of-the-art manufacturing facilities in Mascot, Australia.

The global shortage of necessary reagents and kits to adequately address SARS-CoV-2 testing has led to the relegation of pathology labs, hospitals, and testing facilities, particularly in Australia and New Zealand by larger suppliers.

In response, AusDiagnostics partnered with the Australian Federal Government in June to pledge the creation of a new facility to meet the current and future demands for sample purification reagents.

The opening of the new state-of-the-art facility coincided with the launch of the new Puryx™ sample purification product line near the end of September. The new production laboratories are outfitted to streamline high-scale manufacturing, with the ability to produce enough kits to facilitate one million extractions per month.

While the imminent focus is on extraction kits for respiratory pathogens, rapid expansion is in progress to meet the demands of the changing market beyond the pandemic as the world begins to transition back to normal operations.

The Puryx™ extraction kits are designed for high throughput and are optimised for open robotic handling platforms. The Puryx™ Rapid extraction kits can

be performed manually or with the aid of a semi-automated platform in as little as 25 minutes, allowing more than 1,400 samples to be purified in a day. Puryx™ Comprehensive kits provide high-purity DNA or RNA extraction on a fully automated MT-Prep™ XL platform, allowing for almost 400 samples per day.

"We're proud to partner with the Federal Government to build this facility to manufacture extraction kits domestically. It's a key effort in securing the entire testing process for COVID-19, respiratory illnesses and other infections," says AusDiagnostics CEO, Scott Gilroy.

"Our research team has been at the forefront of this pandemic and continues to deliver quality innovations in the diagnostics space. We understand the importance of not only providing supply, but also thinking ahead to how we can minimise time from sample collection to actual diagnosis.

"Despite what we might face in the future, AusDiagnostics is committed to providing the highest quality testing products and diagnostics technology so that we will be ready to respond to demands both domestically and internationally."

Puryx™ products are now available.

Contact your local AusDiagnostics representative to find out more.

NEW

Puryx™ sample purification kits

Puryx™ Comprehensive

- **High-purity**
Attain high-purity DNA / RNA for the next step in your workflow.
- **High-throughput**
Perform fully-automated extraction with the MT-Prep™ XL system, or integrate into existing high-throughput platforms in your lab.

Puryx™ Rapid

- **Quick protocol**
Extract DNA / RNA in just 25 minutes.
- **Get started sooner**
Perform extraction manually with everyday laboratory equipment, or easily integrate semi-automation on existing open platforms.



PROUDLY
CELEBRATING
OUR

14TH ANNIVERSARY

AusDiagnostics celebrated 14 years of helping customers in molecular diagnostics and announced new CEO

At the celebration of the Company's 14 year anniversary, Managing Director Keith Stanley announced the appointment of Scott Gilroy as the new CEO of AusDiagnostics on Monday, August 24, 2020.

Announcing Mr Gilroy's appointment, Professor Stanley said: "Scott has not been with us long, but has already made a quantum leap in company performance, dealing with all the

operational challenges caused by the COVID-19 pandemic and rapid expansion of the company.

"He is introducing new tools for management that will enable the company to continue to grow through the next phase of its development."

Reflecting on his appointment, Mr Gilroy said to be part of such progress was a privilege: "I have always maintained a deep love for science and the way it changes our lives for the better. To have the opportunity to lead a dedicated and inspiring group of people at the heart of responding to the COVID-19 pandemic is truly humbling.

"We have some of the finest talent in the diagnostics field, a great culture and collaborative spirit, and dynamic

capabilities in the market, that has enabled our strong and rapid growth. As a company, we have diversified and transitioned into a competitive global organisation. My mission is to build on our success and momentum to deliver even greater innovations and develop further expansion opportunities."



Scott Gilroy
Chief Executive Officer

"As a company, we have diversified and transitioned into a competitive global organisation."

© 2020 AusDiagnostics Pty Ltd. All rights reserved. AusDiagnostics, Puryx, and MT-Prep are trademarks of AusDiagnostics Pty Ltd. E&OE. N20Q3001. 30 Sep 2020.

SUPPORT BEYOND SARS-CoV-2

Don't put other important testing on hold during COVID-19.

**STI and Enteric Pathogen
MT-PCR panels available.**

Contact your local AusDiagnostics representative for more information.

